Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BPMC Blueprint Medicines	$127.85 0.0%	$95.59	$73.04 ▼ $128.24	$8.26B	0.84	1.11 million shs	3.07 million shs
CYTK Cytokinetics	$32.30 +0.7%	$35.24	$29.31 ▼ $61.38	$3.86B	0.59	1.56 million shs	765,773 shs
FOLD Amicus Therapeutics	$6.16 +3.4%	$6.61	$5.81 ▼ $12.65	$1.90B	0.54	2.94 million shs	5.15 million shs
RETA Reata Pharmaceuticals	$172.36	$171.30	$21.83 ▼ $172.46	$6.58B	1.42	1.09 million shs	N/A

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BPMC Blueprint Medicines	0.00%	+26.40%	+30.81%	+47.48%	+23.72%
CYTK Cytokinetics	0.00%	+4.60%	+1.92%	-25.42%	-38.81%
FOLD Amicus Therapeutics	0.00%	+0.82%	+3.01%	-28.62%	-38.71%
RETA Reata Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BPMC Blueprint Medicines	0.8903 of 5 stars	2.2	1.0	0.0	0.0	2.3	0.8	0.6
CYTK Cytokinetics	4.0567 of 5 stars	4.5	1.0	0.0	4.6	2.6	0.8	0.0
FOLD Amicus Therapeutics	3.7884 of 5 stars	3.4	1.0	0.0	4.3	1.9	0.0	1.9
RETA Reata Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BPMC Blueprint Medicines	2.32	Hold	$129.35	1.18% Upside
CYTK Cytokinetics	2.93	Moderate Buy	$72.31	123.86% Upside
FOLD Amicus Therapeutics	2.70	Moderate Buy	$16.22	163.35% Upside
RETA Reata Pharmaceuticals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest RETA, FOLD, BPMC, and CYTK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/5/2025	BPMC Blueprint Medicines	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$102.00 ➝ $129.00
6/5/2025	BPMC Blueprint Medicines	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$88.00 ➝ $129.00
6/4/2025	BPMC Blueprint Medicines	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold	$83.00 ➝ $129.00
6/3/2025	BPMC Blueprint Medicines	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$132.00
6/3/2025	BPMC Blueprint Medicines	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/3/2025	BPMC Blueprint Medicines	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/3/2025	BPMC Blueprint Medicines	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/3/2025	BPMC Blueprint Medicines	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Perform
6/3/2025	BPMC Blueprint Medicines	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/3/2025	BPMC Blueprint Medicines	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$150.00 ➝ $135.00
5/29/2025	CYTK Cytokinetics	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$103.00 ➝ $84.00

(Data available from 6/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BPMC Blueprint Medicines	$562.12M	14.69	N/A	N/A	$4.67 per share	27.38
CYTK Cytokinetics	$19.22M	200.72	N/A	N/A	($3.94) per share	-8.20
FOLD Amicus Therapeutics	$543.14M	3.49	N/A	N/A	$0.63 per share	9.78
RETA Reata Pharmaceuticals	$23.48M	280.05	N/A	N/A	($1.79) per share	-96.29

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BPMC Blueprint Medicines	-$67.09M	-$2.47	N/A	196.69	N/A	-13.19%	-77.49%	-20.84%	7/30/2025 (Estimated)
CYTK Cytokinetics	-$526.24M	-$5.29	N/A	N/A	N/A	-17,906.25%	N/A	-50.21%	8/6/2025 (Estimated)
FOLD Amicus Therapeutics	-$151.58M	-$0.09	N/A	14.33	1.51	-10.62%	12.44%	2.60%	8/14/2025 (Estimated)
RETA Reata Pharmaceuticals	-$311.90M	N/A	0.00	N/A	N/A	N/A	-922.50%	-73.39%	N/A

Latest RETA, FOLD, BPMC, and CYTK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/6/2025	Q1 2025	CYTK Cytokinetics	-$1.41	-$1.36	+$0.05	-$1.36	$2.77 million	$1.60 million
5/1/2025	Q1 2025	BPMC Blueprint Medicines	-$0.42	-$0.74	-$0.32	$0.01	$158.31 million	$149.41 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BPMC Blueprint Medicines	N/A	N/A	N/A	N/A	N/A
CYTK Cytokinetics	N/A	N/A	N/A	N/A	N/A
FOLD Amicus Therapeutics	N/A	N/A	N/A	N/A	N/A
RETA Reata Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BPMC Blueprint Medicines	1.15	2.85	2.80
CYTK Cytokinetics	5.93	9.28	9.28
FOLD Amicus Therapeutics	2.01	3.39	2.42
RETA Reata Pharmaceuticals	0.84	3.21	3.19

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BPMC Blueprint Medicines	N/A
CYTK Cytokinetics	N/A
FOLD Amicus Therapeutics	N/A
RETA Reata Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
BPMC Blueprint Medicines	4.21%
CYTK Cytokinetics	3.40%
FOLD Amicus Therapeutics	2.20%
RETA Reata Pharmaceuticals	26.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BPMC Blueprint Medicines	640	64.58 million	61.22 million	Optionable
CYTK Cytokinetics	250	119.43 million	114.00 million	Optionable
FOLD Amicus Therapeutics	480	307.93 million	292.23 million	Optionable
RETA Reata Pharmaceuticals	321	38.15 million	27.93 million	Optionable

RETA, FOLD, BPMC, and CYTK Headlines

Recent News About These Companies

Biogen axes asset from $7.3B buyout, along with Alzheimer’s and Parkinson’s prospects

February 12, 2025 | fiercebiotech.com

Arbe Robotics (NASDAQ:ARBE) Stock Quotes, Forecast and News Summary

November 1, 2024 | benzinga.com

What to Know: How Israel Could Retaliate Against Iran

October 27, 2024 | nytimes.com

Reta Hendrickson

September 11, 2024 | newsandsentinel.com

Reata rockets on data for Nrf2 drug reacquired from AbbVie

August 8, 2024 | pharmaphorum.com

Lazard hires veteran healthcare dealmaker Colocci as vice chairman

May 9, 2024 | investing.com

Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement

April 18, 2024 | accesswire.com

Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement

April 16, 2024 | accesswire.com

Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement

April 11, 2024 | accesswire.com

Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement

April 9, 2024 | accesswire.com

Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement

April 4, 2024 | accesswire.com

Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement

April 2, 2024 | accesswire.com

Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement

March 28, 2024 | accesswire.com

Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement

March 26, 2024 | accesswire.com

Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement

March 21, 2024 | accesswire.com

Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement

March 19, 2024 | accesswire.com

Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement

March 14, 2024 | accesswire.com

Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement

March 12, 2024 | accesswire.com

Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement

March 7, 2024 | accesswire.com

Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. (RETA) an Upcoming Claims Deadline in a Class Action Settlement

March 5, 2024 | accesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Walmart Stock Alert: Big Price Move Expected Soon
By Thomas Hughes | May 15, 2025
View Walmart Stock Alert: Big Price Move Expected Soon
Can Ross Stores Be the Safety Cushion In Retail Stocks?
By Gabriel Osorio-Mazilli | May 27, 2025
View Can Ross Stores Be the Safety Cushion In Retail Stocks?
An Acquisition Just Made Dick's the Most Exciting Stock in Retail
By Gabriel Osorio-Mazilli | May 15, 2025
View An Acquisition Just Made Dick's the Most Exciting Stock in Retail
TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain
By Thomas Hughes | May 23, 2025
View TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain
Retail Investors Are Betting Big on Rocket Lab—Should You Too?
By Ryan Hasson | May 16, 2025
View Retail Investors Are Betting Big on Rocket Lab—Should You Too?

RETA, FOLD, BPMC, and CYTK Company Descriptions

Blueprint Medicines NASDAQ:BPMC

$127.85 -0.05 (-0.04%)

Closing price 06/6/2025 04:00 PM Eastern

Extended Trading

$127.72 -0.13 (-0.10%)

As of 06/6/2025 07:58 PM Eastern

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Cytokinetics NASDAQ:CYTK

$32.30 +0.22 (+0.69%)

Closing price 06/6/2025 04:00 PM Eastern

Extended Trading

$32.30 0.00 (0.00%)

As of 06/6/2025 07:54 PM Eastern

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

Amicus Therapeutics NASDAQ:FOLD

$6.16 +0.20 (+3.36%)

Closing price 06/6/2025 04:00 PM Eastern

Extended Trading

$6.19 +0.03 (+0.50%)

As of 06/6/2025 06:50 PM Eastern

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

Reata Pharmaceuticals NASDAQ:RETA

Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone to treat Friedreich's ataxia; and conduct various form of CKD, such as, type 1 and type 2 diabetic CKD, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and bardoxolone for the treatment of autosomal dominant polycystic kidney disease. In addition, the company has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time